Baxter voluntarily withdraws specific Novum pumps due to reported complications leading to 79 injuries and 2 fatalities.
## Baxter's Novum IQ Large Volume Pump Faces Safety Concerns and Recall
Baxter's Novum IQ large volume infusion pumps have been the subject of recent recalls and performance issues, leading to concerns about the device's safety.
### Recall and Safety Concerns
The Food and Drug Administration (FDA) has published an early alert about a problem linked to 79 serious injuries and two deaths with Baxter's Novum IQ large volume pump [1][3][4]. The alert is based on a recall notice that Baxter received from the FDA in June [4].
### Performance Issues
The main issue with the Novum IQ large volume pump is its performance when transitioning from a low flow rate to a higher one, particularly when the rate change is more than doubled. This can lead to variable levels of under-infusion, potentially resulting in no drug delivery at all [1]. Additionally, Baxter has identified issues related to set misloading, which can cause over- and under-infusion [1].
### Corrective Actions
Healthcare providers are advised to change the pump's IV administration set or switch to another pump whenever possible. If this cannot be done immediately, users should manually adjust the tubing placement before altering the drug delivery rate [1]. The pumps are still usable with these corrections and do not need to be returned.
### Impact on the Market
1. **Regulatory Response**: The FDA's early alert and Baxter's correction efforts reflect a proactive approach to addressing device safety issues. This vigilance is likely to influence other manufacturers to be more transparent about potential problems [3].
2. **Market Trust**: The recall and safety concerns may impact consumer and healthcare provider trust in Baxter's products. Companies in the medical device sector will need to assure customers of their products' reliability to maintain market share [5].
3. **Innovation and Safety Protocols**: The Novum IQ issue highlights the need for continuous monitoring and improvement of medical devices. Companies may need to invest more in testing and compliance to prevent similar problems in the future [1][4].
4. **Competition**: The recall could provide opportunities for competitors to fill the gap in the market by offering safer alternatives. However, it also underscores the importance of rigorous safety standards across the industry [5].
Baxter has also advised users to change the pump and infusion set at a time when a delay in treatment would not harm the patient. The company has provided recommendations for healthcare professionals who cannot change the pump without causing an unacceptable delay in infusion [1].
Other customer reports have described cases of overinfusion and underinfusion potentially caused by set misloading with the Novum IQ large volume pump [1]. In response, Baxter has issued a correction letter for the Novum IQ large volume pump, advising users on how to prevent underinfusion that could put infants at risk [2].
The new problems with the Novum IQ large volume pump include the pump underinfusing when transitioning to a higher flow rate, which was not mentioned in earlier facts [1]. Baxter has not yet announced a replacement pump for the Novum IQ large volume pump.
[1] FDA (2025). Early Communication - Potential Issues with Baxter's Novum IQ Large Volume Pump. Retrieved from https://www.fda.gov/medical-devices/safety-communications/early-communication-potential-issues-baxters-novum-iq-large-volume-pump [2] Baxter Healthcare Corporation (2025). Correction Letter: Baxter's Novum IQ Large Volume Pump. Retrieved from https://www.baxter.com/content/dam/baxter/global/en/pdf/corporate/pdfs/us-correction-letter-novum-iq-large-volume-pump.pdf [3] Moody's (2025). FDA Early Alert on Baxter's Novum IQ Large Volume Pump: Implications for the Medical Device Industry. Retrieved from https://www.moodys.com/research/Moodys-Early-Alert-on-Baxters-Novum-IQ-Large-Volume-Pump--Implications-for-the-Medical-Device-Industry-PR_vln19428614 [4] Reuters (2025). Baxter Recalls Infusion Pumps Over Safety Concerns, Two Deaths Reported. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/baxter-recalls-infusion-pumps-over-safety-concerns-two-deaths-reported-2025-06-28/ [5] McKinsey & Company (2025). The Impact of Recalls on Medical Device Companies. Retrieved from https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/the-impact-of-recalls-on-medical-device-companies
- The recent recalls and performance issues with Baxter's Novum IQ large volume pump have raised concerns about the device's safety in the realm of medtech.
- FDA's early alert about the Novum IQ large volume pump is indicative of a growing interest in devices analytics and regulation within healthcare, as it highlights potential medical-conditions associated with the device.
- The recall may potentially affect Healthcare-and-wellness for patients, as issues related to set misloading might lead to over- or under-infusion, threatening their health.
- AI and science might provide solutions in addressing these issues, as advanced analytics could be used to predict and prevent similar problems in the future, promoting health-and-wellness and ensuring the efficacy of therapies-and-treatments.
- Given the FDA's response to Baxter's recall, it is essential for companies in the medtech industry to prioritize the safety of their devices and openly communicate about potential problems for the maintenance of consumer and healthcare provider trust.
- In light of the recall, competitors in the healthcare sector could potentially capitalize on the opportunity to introduce safer alternatives into the market, fostering innovation and competition in the medtech industry.
- To prevent future recalls, companies in the medtech industry should invest more in testing and compliance, emphasizing a commitment to safety and continuous improvement in the realm of healthcare.
